
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd is positioned for significant revenue growth as a result of a recent study that may enable glioblastoma patients to start treatment 2-3 months earlier than current practices, potentially increasing revenue per patient by approximately 20-30%. Additionally, the company's expanding presence in key markets like Germany is expected to drive accelerating growth in active patients, serving as a strong indicator of future revenue trajectories through 2026. The anticipated contribution from new markets over the next 12-18 months further supports NovoCure's positive outlook, supplementing existing patient growth drivers.
Bears say
NovoCure Ltd faces a challenging financial outlook, as projected revenue growth is expected to lead to a significant decline in EBITDA over the upcoming quarters. Despite the anticipation of revenues ramping up, estimates indicate that the company may only achieve breakeven EBITDA levels by 2027. This extended timeline for reaching financial stability raises concerns about the company's short-term profitability and overall financial health.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares